FBR Upgrades Keryx Biopharma To Outperform, Sees Meaningful Auryxia Sales & Potential Label Expansion
February 29, 2016 at 07:53 AM EST
FBR’s Christopher S. James upgraded the rating for Keryx Biopharmaceuticals (NASDAQ: KERX) from Market Perform to Outperform, ...